Richard Schlegel

C. Richard Schlegel
Nationality	American
Alma mater	Rutgers University (B.A.) Northwestern University (MD-PhD)
Occupation	Professor and Chair of the Department of Pathology
Employer	Georgetown University
Known for	Co-inventor of the HPV vaccine and CRC technology

C. Richard Schlegel is an American scientist and professor. He is the Chair of the Department of Pathology at Georgetown University. He is best known as the co-inventor of the HPV vaccine and Conditionally Reprogrammed Cells (CRC) technology.

Schlegel met his future wife, Susan Banks-Schlegel, in the microbiology laboratory in which he worked after his first year at Northwestern University. They were married in 1978. They have three children together.

Schlegel received his bachelor's degree in biological sciences from Rutgers University in 1968. After graduating, he went on to enroll at Northwestern University, where he planned to study pediatrics. However, after working at a microbiology laboratory at Northwestern University the summer after his first year, he decided instead to enroll in the MD-PhD program. After graduating, Schlegel went to Harvard University in 1975 to serve his residency and perform postdoctoral research in pathology.

Following his work at Harvard University, Schlegel and his wife both began working at the National Institutes of Health. Schlegel worked in the National Cancer Institute's Laboratory of Molecular Biology, and there he began precursory work that would contribute to his later development of the HPV vaccine. He first studied a bovine papillomavirus, then focused on the E5, E6, and E7 proteins of the human papillomavirus. In 1988, Schlegel began working with A. Bennett Jenson, a member of the Georgetown University faculty. When Schlegel began working as an associate professor at Georgetown University in 1990, their work gained momentum. In 1995, they published a paper in the Proceedings of the National Academy of Sciences that demonstrated that their vaccine could protect against a virus like that seen in cervical cancer. The main patent on the vaccine was granted in 2005, and the Food and Drug Administration approved it in June 2006.

...
Wikipedia